Key result
Fruitflow at doses of 75 mg, 150 mg, and 300 mg equivalently reduced platelet aggregation from baseline by 12.9%, 12.0%, and 17.7% respectively, whereas 30 mg and placebo had no significant effect.
Why the study?
Fruitflow is a dietary antiplatelet used in primary prevention, but the range of intakes linked to efficacy and the variability in response required investigation.
Does Fruitflow reduce platelet aggregation and thrombin generation capacity in male subjects?
RCT (n=12)
Double-blind
Randomized
No
Does Fruitflow reduce platelet aggregation and thrombin generation capacity in male subjects?
Absolute Event Rate: -12% vs 3%
p-value: p=<0.05
Fruitflow at doses between 75 mg and 300 mg effectively reduces platelet aggregation and thrombin generation capacity in men, suggesting a personalized approach to dosing may be beneficial.
Supports 75 mg minimum effective Fruitflow dose for primary prevention; extends pilot dose-equivalence data but leaves optimal regimens open.
BACKGROUND: The water-soluble tomato extract, Fruitflow® is a dietary antiplatelet which can be used to lower platelet aggregability in primary preventative settings. We carried out a pilot study to investigate the range of intakes linked to efficacy and to make an initial assessment of variability in response to Fruitflow®. METHODS: Platelet response to adenosine diphosphate (ADP) agonist and thrombin generation capacity were monitored at baseline and 24 h after consuming 0, 30, 75, 150 or 300 mg of Fruitflow® in a randomized, double-blinded crossover study in male subjects 30-65 years of age (N = 12). Results were evaluated for equivalence to the standard 150 mg dose. RESULTS: Results showed that the changes from baseline aggregation and thrombin generation observed after the 75 mg, 150 mg, and 300 mg supplements were equivalent. Aggregation was reduced from baseline by - 12.9 ± 17.7%, - 12.0 ± 13.9% and - 17.7 ± 15.7% respectively, while thrombin generation capacity fell by - 8.6 ± 4.1%, - 9.2 ± 3.1% and - 11.3 ± 2.3% respectively. Effects observed for 0 mg and 30 mg supplements were non-equivalent to 150 mg and not different from baseline (aggregation changed by 3.0 ± 5.0% and - 0.7 ± 10.2% respectively, while thrombin generation changed by 0.8 ± 3.0% and 0.8 ± 3.1% respectively). CONCLUSIONS: The data suggest that the efficacious range for Fruitflow® lies between 75 mg and 300 mg, depending on the individual. It may be pertinent to personalize the daily intake of Fruitflow® depending on individual platelet response. TRIAL REGISTRATION: ISRCTN53447583 , 24/02/2021.
No takes yet. Share an insight, caveat, or question.
Das et al. (2021) conducted an RCT in Platelet hyperaggregability (n=12). Fruitflow vs. Tapioca starch placebo was evaluated on Percentage change from baseline in platelet aggregation in response to ADP agonist at 24 hours (p=<0.05). Fruitflow at doses of 75 mg, 150 mg, and 300 mg equivalently reduced platelet aggregation from baseline by 12.9%, 12.0%, and 17.7% respectively, whereas 30 mg and placebo had no significant effect.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: